Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> Perillyl alcohol [536-59-4]

Perillyl alcohol [536-59-4]

Imprimer Imprimer
Identifiez-vous

Référence HY-N7000-100mg

Conditionnement : 100mg

Marque : MedChemExpress

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Description

Perillyl alcohol is an orally active monoterpene. Perillyl alcohol exhibits multiple activities such as analgesic, anti-inflammatory, anti-tumor, anti-angiogenic, and anti-nociceptive effects. Perillyl alcohol can induce apoptosis and cell cycle arrest in tumor cells[1][2][3][4].

In Vitro

Perillyl alcohol (0-1.0 mM; 0-48 h) significantly increases caspase-3 activity and inhibits the phosphorylation level of Akt in BLMVECs[1].
Perillyl alcohol (0.2-1 mM; 24-72 h) reduces the basal secretion of VEGF in a concentration- and time-dependent manner in K562, B16, and MDA-MB-231 cells[1].
Perillyl alcohol (0.7-1 mM; 0-48 h) induces apoptosis, inhibits ROS production, and suppresses the expression of Ras protein and the activation of downstream targets in the 1984-1 mouse melanoma cell line[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Perillyl alcohol Related Antibodies

Western Blot Analysis[1]

Cell Line: Bovine lung microvascular endothelial cells (BLMVECs)
Concentration: 0.5 mM
Incubation Time: 15, 30, 60 and 120 min
Result: Inhibited the phosphorylation level of AKT without affecting total Akt levels.
In Vivo

Perillyl alcohol (2-20 nmoles/cm2; incubation; single dose; 48 h) reduces the number of blood vessels in a dose-dependent manner in the chicken embryo chorioallantoic membrane model[1].
Perillyl alcohol (10 mM; topical application; three times a week; 38 weeks) has anti-melanoma activity in the TPras mouse model[2].
Perillyl alcohol (50-100 mg/kg; intraperitoneal injection; single dose) has analgesic and anti-nociceptive activities in mice[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: DMBA treated (HY-W011845) TPras transgenic mice[2]
Dosage: 10 mM
Administration: Topical application; three times a week; 38 weeks
Result: Led to a 25-35% reduction in melanoma incidence.
Delayed the onset of tumor development.
Animal Model: Adult male albino Swiss mice (25-35 g) aged 2-3 months old[2].
Acetic Acid (HY-Y0319)-induced writhing model; Formalin-induced nociception model
Dosage: 50, 75 or 100 mg/kg
Administration: Intraperitoneal injection (i.p.); single dose
Result: Significantly reduced the number of writhings in the acetic acid-induced writhing test and the paw licking time in both phases of the formalin-induced pain test.
Did not cause significant tissue changes in the hippocampus and striatum at 50 and 75 mg/kg, while at 100 mg/kg, it caused mild lesions in some mice.
Essai clinique
Masse moléculaire

152.24

Formule

C10H16O
CAS No.
Appearance

Liquid (Density: 0.96 g/cm3)

Color

Colorless to light yellow

SMILES

OCC1=CCC(C(C)=C)CC1
Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvant et solubilité
In Vitro: 

DMSO : 100 mg/mL (656.86 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 6.5686 mL 32.8429 mL 65.6858 mL
5 mM 1.3137 mL 6.5686 mL 13.1372 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (16.42 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (16.42 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références